Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans.

The disposition of methoxyphenamine (o-methoxy-N,alpha-dimethylphenethylamine) and three of its metabolites was studied in five healthy volunteers on three occasions, with the urine pH separately under uncontrolled, acidic, and basic conditions. All five volunteers were extensive metabolizers of debrisoquine and methoxyphenamine, the latter with respect to O-demethylation and aromatic 5-hydroxylation. The plasma peak concentration and the area under the curve of methoxyphenamine from 0 to infinity did not differ significantly during the three phases of the study. However, on the average, its renal clearance increased by fivefold and its plasma terminal half-life decreased by twofold in the acidic as compared with the alkaline urine condition. The urinary excretions of methoxyphenamine and its metabolites N-desmethylmethoxyphenamine and O-desmethylmethoxyphenamine were significantly enhanced in the uncontrolled pH and the acidic urine conditions as compared with the alkaline urine condition. By contrast, the urinary excretion of the 5-hydroxymethoxyphenamine metabolite was not significantly affected by urinary pH variations. The mean urinary excretion ratios methoxyphenamine: O-desmethylmethoxyphenamine and N-desmethylmethoxyphenamine: O-desmethylmethoxyphenamine did not differ significantly during the three phases of the study, whereas the methoxyphenamine:5-hydroxymethoxyphenamine and N-desmethylmethoxyphenamine:5-hydroxymethoxyphenamine ratios were significantly altered during the alkaline phase as compared with the other two phases. Therefore, the ratios in terms of O-desmethylmethoxyphenamine are recommended for phenotyping individuals when using methoxyphenamine as a metabolic probe.

[1]  G McKay,et al.  Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[2]  K. Midha,et al.  Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. , 1985, Canadian journal of physiology and pharmacology.

[3]  K. Midha,et al.  METHOXYPHENAMINE AND DEXTROMETHORPHAN AS SAFE PROBES FOR DEBRISOQUINE HYDROXYLATION POLYMORPHISM , 1984, The Lancet.

[4]  K. Midha,et al.  Gas chromatographic quantitation of methoxyphenamine and three of its metabolites in plasma. , 1984, Journal of chromatography.

[5]  K. Midha,et al.  Identification of new secondary metabolites of methoxyphenamine in man. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[7]  K. Midha,et al.  Metabolism of methoxyphenamine in man and in monkey. , 1976, Drug metabolism and disposition: the biological fate of chemicals.

[8]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[9]  John G. Wagner,et al.  Fundamentals of Clinical Pharmacokinetics , 1975 .

[10]  A. Neville,et al.  Letter: In-vitro production of carcinoembryonic antigen by normal and neoplastic colon. , 1973, Lancet.

[11]  J. Axelrod,et al.  EFFECTS OF URINARY pH ON AMPHETAMINE METABOLISM , 1971, Annals of the New York Academy of Sciences.

[12]  A. Beckett,et al.  Urinary excretion kinetics of amphetamine in man , 1965, The Journal of pharmacy and pharmacology.